Brody Arthur L, Mischel Anna K, Sanavi Andre Y, Wong Alvin, Bahn Ji Hye, Minassian Arpi, Morgan Erin E, Rana Brinda, Hoh Carl K, Vera David R, Kotta Kishore K, Miranda Alannah H, Pocuca Nina, Walter Thomas J, Guggino Natalie, Beverly-Aylwin Renee, Meyer Jeffrey H, Vasdev Neil, Young Jared W
Department of Psychiatry, University of California San Diego, San Diego, CA, USA.
Department of Research, VA San Diego Healthcare System, San Diego, CA, USA.
Neuropsychopharmacology. 2025 Mar;50(4):695-704. doi: 10.1038/s41386-024-02035-6. Epub 2025 Jan 1.
People living with HIV (HIV+) are roughly twice as likely to smoke cigarettes (Smok+) as the general population. With the advent of effective antiretroviral therapies, it is increasingly important to understand the effects of chronic HIV infection and cigarette smoking on brain function and cognition since HIV+ individuals have heightened neuroinflammation and cognitive deficits even with such therapies. Based on prior studies demonstrating that smoking reduces a marker for neuroinflammation in HIV- individuals, we hypothesized that HIV+/Smok+ individuals would have less neuroinflammation and better cognitive control than HIV+/Smok- individuals. Fifty-nine participants (HIV-/Smok- [n = 16], HIV-/Smok+ [n=14], HIV+/Smok- [n = 18], and HIV+/Smok+ [n = 11]) underwent baseline eligibility tests, positron emission tomography (PET) scanning to determine levels of a marker for neuroinflammation, and assessment of cognitive control with the reverse-translated 5-choice continuous performance test (5C-CPT), with smokers having smoked to satiety prior to testing. For the PET data, a significant effect of smoking status on whole brain (WB) standardized uptake value (SUV) was found between HIV+/Smok+ and HIV+/Smok- participants (due to 18.8% lower WB SUV in the HIV+/Smok+ group). HIV+/Smok- participants exhibited a mean 13.5% higher WB SUV than HIV-/Smok- participants. For the 5C-CPT, HIV+/Smok+ participants performed significantly better than HIV+/Smok- participants (d prime), and HIV+/Smok- participants performed worse than HIV-/Smok- participants. Thus, HIV+/Smok+ individuals demonstrated lower levels of the neuroinflammation marker and better cognitive control than HIV+/Smok- individuals. Given that HIV+ individuals whose HIV is well-controlled can still have chronic neurocognitive complications, study results suggest possible paths for future research into nicotine-related treatments to prevent such complications.
感染艾滋病毒(HIV+)的人吸烟(Smok+)的可能性大约是普通人群的两倍。随着有效抗逆转录病毒疗法的出现,了解慢性HIV感染和吸烟对脑功能和认知的影响变得越来越重要,因为即使接受了此类疗法,HIV+个体仍存在神经炎症加剧和认知缺陷的问题。基于先前的研究表明吸烟可降低HIV阴性个体的神经炎症标志物,我们假设HIV+/Smok+个体比HIV+/Smok-个体具有更少的神经炎症和更好的认知控制能力。59名参与者(HIV-/Smok- [n = 16],HIV-/Smok+ [n = 14],HIV+/Smok- [n = 18],和HIV+/Smok+ [n = 11])接受了基线资格测试、正电子发射断层扫描(PET)以确定神经炎症标志物的水平,以及使用反向翻译的5选连续性能测试(5C-CPT)评估认知控制能力,吸烟者在测试前已吸烟至饱腹感。对于PET数据,在HIV+/Smok+和HIV+/Smok-参与者之间发现吸烟状态对全脑(WB)标准化摄取值(SUV)有显著影响(由于HIV+/Smok+组的WB SUV低18.8%)。HIV+/Smok-参与者的WB SUV比HIV-/Smok-参与者平均高13.5%。对于5C-CPT,HIV+/Smok+参与者的表现明显优于HIV+/Smok-参与者(d值),且HIV+/Smok-参与者的表现比HIV-/Smok-参与者差。因此,与HIV+/Smok-个体相比,HIV+/Smok+个体表现出较低水平的神经炎症标志物和更好的认知控制能力。鉴于HIV得到良好控制的HIV+个体仍可能出现慢性神经认知并发症,研究结果为未来研究尼古丁相关治疗以预防此类并发症提供了可能的途径。